MITRAL VALVE DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In June 2024, Foldax, Inc., a leader in the development of innovative, polymer heart valves, announced positive 30-day results from a clinical study of its TRIA mitral surgical heart valve, featuring the novel LifePolymer material, conducted in India. The study involved 67 patients, primarily females aged 19 to 67 with rheumatic heart disease. At 30 days post-surgery, the TRIA valve demonstrated favorable safety and hemodynamic performance, with imaging showing no signs of calcification or leaflet deterioration. These findings suggest that the TRIA valve could offer a durable, non-animal tissue heart valve option that may not require long-term anticoagulation therapy
• In November 2021, Medtronic plc, a medical device company, shared early results from the Intrepid transcatheter mitral valve replacement (TMVR) system, designed for patients with severe, symptomatic mitral valve regurgitation (MR) using the transfemoral access route. Data from the first five patients enrolled in an Early Feasibility Study demonstrated 100% survival, no strokes, and only trace or no MR in all implanted patients at 30 days.
• In September 2021, Abbott, a global pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves. These innovations, built on Abbott's Epic surgical valve platform, expand therapeutic options for individuals with aortic or mitral valve disease.
• In June 2021, CORCYM, the newly independent medical device company committed to offering the best solutions for structural heart disease, has officially announced the global launch of its operations.
• In January 2020, Abbott, a global pharmaceutical company, received CE Mark approval for its Tendyne Transcatheter Mitral Valve Implantation (TMVI) system, enabling its use in Europe for treating mitral regurgitation (MR) in patients requiring heart valve replacement